FDA Delays Force Biotech Closure, Raising Concerns About Drug Development Pipeline

References

1. 1.Chen, E. (2026). How a four-month FDA delay forced a small biotech company to close its doors. STAT News. https://www.statnews.com/2026/04/06/fda-delay-cited-in-closure-kezar-life-sciences-biotech-startup/
2. 2.Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020). Diagnosis and management of autoimmune hepatitis in adults and children. Hepatology, 72(2), 671-722. https://doi.org/10.1002/hep.31065
3. 3.DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33. https://doi.org/10.1016/j.jhealeco.2016.01.012
4. 4.European Association for the Study of the Liver. (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology, 63(4), 971-1004. https://doi.org/10.1016/j.jhep.2015.06.030
5. 5.Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Needleman, K. I., Paepe, B., Preti, A., Spreafico, A., Westermark, K., & Hivert, V. (2020). Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nature Reviews Drug Discovery, 19(2), 93-111. https://doi.org/10.1038/s41573-020-0049-9
6. 6.Therapeutic Goods Administration. (2023). Orphan drug designation program: Annual report 2022-23. Australian Government Department of Health. https://www.tga.gov.au/resources/publication/publications/orphan-drug-designation-program-annual-report-2022-23
7. 7.Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020). FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA, 323(2), 164-176. https://doi.org/10.1001/jama.2020.20615
8. 8.Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191-200. https://doi.org/10.1038/nrd3681